Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well pazopanib hydrochloride works after
leuprolide or goserelin in treating patients with relapsed prostate cancer. Pazopanib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of
prostate cancer cells. Antihormone therapy, such as leuprolide acetate or goserelin acetate,
may lessen the amount of androgens made by the body. Giving pazopanib after leuprolide or
goserelin may be an effective treatment for prostate cancer